US Stock MarketDetailed Quotes
BDRX Biodexa Pharmaceuticals
- 4.6600
- +0.0900+1.97%
Trading Nov 25 12:01 ET
2.71MMarket Cap-2P/E (TTM)
4.8800High4.2200Low36.59KVolume4.8200Open4.5700Pre Close165.07KTurnover13.02%Turnover RatioLossP/E (Static)580.84KShares103.000052wk High0.25P/B1.31MFloat Cap3.500052wk Low--Dividend TTM281.14KShs Float14680000.0000Historical High--Div YieldTTM14.44%Amplitude3.5000Historical Low4.5110Avg Price1Lot Size
Biodexa Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | (FY)Dec 31, 2017 | (FY)Dec 31, 2016 | (FY)Dec 31, 2015 | (FY)Dec 31, 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -45.49%381K | 20.93%699K | 68.51%578K | -49.11%343K | -65.22%674K | 95.96%1.94M | -25.25%989K | -3.78%1.32M | 775.80%1.38M | 6.80%157K |
| Operating revenue | -45.49%381K | 20.93%699K | 221.11%578K | -73.29%180K | -65.22%674K | 95.96%1.94M | -25.25%989K | -3.78%1.32M | 775.80%1.38M | 6.80%157K |
| Cost of revenue | -20.43%4.07M | 9.82%5.11M | -23.30%4.65M | -22.63%6.07M | -16.20%7.84M | 12.37%9.36M | 7.75%8.33M | -11.96%7.73M | 141.28%8.78M | 89.04%3.64M |
| Gross profit | 16.46%-3.69M | -8.24%-4.41M | 28.80%-4.08M | 20.14%-5.73M | 3.40%-7.17M | -1.10%-7.42M | -14.56%-7.34M | 13.48%-6.41M | -112.67%-7.41M | -95.84%-3.48M |
| Operating expense | -4.25%4.33M | 54.69%4.52M | -40.92%2.92M | 19.21%4.95M | -5.58%4.15M | -0.95%4.39M | 36.70%4.44M | -41.14%3.25M | 25.15%5.51M | 61.89%4.41M |
| Selling and administrative expenses | -4.40%4.34M | 54.18%4.54M | -40.58%2.95M | 19.07%4.96M | -5.23%4.16M | -0.95%4.39M | 36.70%4.44M | -41.14%3.25M | 25.15%5.51M | 61.89%4.41M |
| -Selling and marketing expense | ---- | ---- | ---- | ---- | --323K | --0 | --170K | --0 | --605K | --0 |
| -General and administrative expense | -4.40%4.34M | 54.18%4.54M | -40.58%2.95M | 29.08%4.96M | -12.59%3.84M | 3.00%4.39M | 31.46%4.27M | -33.88%3.25M | 11.42%4.91M | 61.89%4.41M |
| Other operating expenses | 36.36%-14K | 8.33%-22K | -100.00%-24K | ---12K | ---- | ---- | ---- | ---- | ---- | ---- |
| Operating profit | 10.28%-8.01M | -27.64%-8.93M | 34.42%-7M | 5.72%-10.67M | 4.21%-11.32M | -0.33%-11.82M | -22.01%-11.78M | 25.28%-9.65M | -63.79%-12.92M | -75.31%-7.89M |
| Net non-operating interest income expense | 275.00%42K | 45.45%-24K | -33.33%-44K | 62.92%-33K | 84.79%-89K | -522.34%-585K | -203.30%-94K | 89.58%91K | 131.37%48K | 60.16%-153K |
| Non-operating interest income | 186.21%83K | --29K | --0 | -87.50%1K | 300.00%8K | -86.67%2K | -90.85%15K | 209.43%164K | 562.50%53K | 700.00%8K |
| Non-operating interest expense | -22.64%41K | 20.45%53K | 29.41%44K | -64.95%34K | -83.48%97K | 438.53%587K | 49.32%109K | 1,360.00%73K | -96.89%5K | -35.08%161K |
| Other net income (expense) | 4.06%487K | -50.00%468K | 107.33%936K | -12.77M | ||||||
| Gain on sale of security | 4.06%487K | -50.00%468K | 335.77%936K | ---397K | ---- | ---- | ---- | ---- | ---- | ---- |
| Special income (charges) | ---- | ---- | ---- | ---12.37M | --0 | --0 | ---1.5M | --0 | --0 | ---1.8M |
| -Less:Impairment of capital assets | ---- | ---- | ---- | --12.37M | --0 | --0 | --1.5M | --0 | --0 | --1.8M |
| Income before tax | 11.82%-7.49M | -39.01%-8.49M | 73.98%-6.11M | -114.87%-23.47M | 11.91%-10.92M | 4.39%-12.4M | -54.63%-12.97M | 25.32%-8.39M | -14.15%-11.23M | -101.52%-9.84M |
| Income tax | 51.20%-406K | -28.79%-832K | 49.57%-646K | 28.24%-1.28M | 12.16%-1.79M | -60.63%-2.03M | 43.20%-1.27M | -96.56%-2.23M | -11.30%-1.13M | -27.41%-1.02M |
| Net income | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | 6.44%-15.03M | 20.33%-16.06M | -99.64%-20.16M | -14.48%-10.1M | -116.01%-8.82M |
| Net income continuous Operations | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -142.82%-22.19M | 11.86%-9.14M | 11.42%-10.37M | -89.99%-11.71M | 38.99%-6.16M | -14.48%-10.1M | -116.01%-8.82M |
| Net income discontinuous operations | ---- | ---- | ---- | ---- | 79.69%-947K | -6.95%-4.66M | 68.87%-4.36M | ---14M | ---- | ---- |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | 6.44%-15.03M | 20.33%-16.06M | -99.64%-20.16M | -14.48%-10.1M | -116.01%-8.82M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Net income attributable to common stockholders | 7.54%-7.08M | -40.22%-7.66M | 75.39%-5.46M | -120.02%-22.19M | 32.90%-10.09M | 6.44%-15.03M | 20.33%-16.06M | -99.64%-20.16M | -14.48%-10.1M | -116.01%-8.82M |
| Basic earnings per share | 98.71%-200 | -13.97%-15.5K | 86.87%-13.6K | -3.60%-103.6K | -154.07%-100K | 21.41%-39.36K | 44.11%-50.08K | -55.56%-89.6K | 63.27%-57.6K | -156.8K |
| Diluted earnings per share | 98.71%-200 | -13.97%-15.5K | 86.87%-13.6K | -103.6K | 21.41%-39.36K | 44.11%-50.08K | -55.56%-89.6K | 63.27%-57.6K | -156.8K | |
| Dividend per share | ||||||||||
| Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data